Glucagon-like peptide-1: difference between revisions
Diff·revision 18 → 19·09:25, 16 Feb 2025
Difference between revision 18 and revision 19 of Glucagon-like peptide-1. 4 lines changed; the page grew by 175 bytes.
| Revision 18 — 21:19, 24 Jan 2025 BetaCellBoyd (talk) clarify that the incretin effect is defined by the oral–intravenous comparison 10,017 bytes ±0 | Revision 19 — 09:25, 16 Feb 2025 DPP4_Dagmar (talk) add the counter-regulatory glucagon point, sourced 10,192 bytes +175 | ||
|---|---|---|---|
| 16 | | Primary inactivation = [[Dipeptidyl peptidase-4|DPP-4]] cleavage at Ala<sup>8</sup> | 16 | | Primary inactivation = [[Dipeptidyl peptidase-4|DPP-4]] cleavage at Ala<sup>8</sup> |
| 17 | | Secondary clearance = Renal; neutral endopeptidase | 17 | | Secondary clearance = Renal; neutral endopeptidase |
| + | 18 | <!-- Receptor --> | |
| + | 19 | | Target = [[GLP-1 receptor]] (GLP1R) | |
| + | 20 | | Receptor family = Class B secretin-like GPCR | |
| + | 21 | | Principal coupling = G<sub>s</sub> → adenylyl cyclase → cAMP | |
| 18 | }} | 22 | }} |
| 19 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} | 23 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} |